Hot Biotechnology Stocks Under $5: (ABIO, AEZS, ANDS, ASTN, BPAX)
July 11th, 2010 at 5:03 pm Posted by
As part of The Dean’s commitment to bringing the CollegeStock student body information on a number of diverse penny stocks, today he’s highlighting 5 Hot Biotechnology Stocks Under $5:
ARCA biopharma, Inc. (NASDAQ: ABIO) focuses on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States. The company’s lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator for the treatment of chronic heart failure and other indications. The $29.3 Million company has a Price/Book ratio of 2.4.
AEterna Zentaris, Inc. (NASDAQ: AEZS) operates as a late-stage drug development company specialized in oncology and endocrinology. The Company’s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The $77.9 Million company reported sales of $63.6 Million for the most recent 12 months and has a Price/Book ratio of 21.0.
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) engages in developing medicines for the treatment of hepatitis C. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, Phase I trial product, an oral toll-like receptor 7 for the treatment of hepatitis C and cancer. The $79.9 Million company has a Price/Book ratio of 9.2.
Aastrom Biosciences, Inc. (NASDAQ: ASTM) engages in developing autologous cell products for the treatment of severe, chronic, and cardiovascular diseases. The Company’s preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations in its proprietary tissue repair cell (TRC) technology and investigate them for their ability to aid in the regeneration of tissues. The $43.8 Million company reported sales of $158.0K for the most recent 12 months and has a Price/Book ratio of 2.0.
Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX) is focused on developing products for female sexual health, menopause, contraception, and male hypogonadism. The company products include Elestrin, a transdermal estradiol (estrogen) gel; LibiGel, a transdermal testosterone gel that is in Phase III development for the treatment of female sexual dysfunction; Pill-Plus for the treatment of female sexual dysfunction; and Bio-T-Gel, a transdermal testosterone gel in development. The $105.1 Million company reported sales of $3.5 Million for the most recent 12 months and has a Price/Book ratio of 4.8.
